{
    "pmcid": "11277385",
    "qa_pairs": {
        "How does the combination of Cv2.3194 and Cv2.3132 antibodies enhance neutralization efficacy?": [
            "By exhibiting local dose-dependent synergy in neutralizing SARS-CoV-2 variants in vitro.",
            "By targeting the same epitope, increasing binding strength.",
            "By preventing viral entry through dual ACE2 receptor blockade.",
            "By enhancing the immune response through cytokine release."
        ],
        "What is the primary target of the Cv2.3194 antibody in the SARS-CoV-2 spike protein?": [
            "Receptor-binding motif (RBM) within the RBD",
            "N-terminal domain (NTD)",
            "Heptad repeat 2 (HR2) region",
            "S2 stalk"
        ],
        "What is the significance of the Cv2.3132 antibody's target region in terms of conservation across sarbecoviruses?": [
            "It is highly conserved, suggesting potential for broad-spectrum neutralization.",
            "It is variable, limiting its neutralization potential.",
            "It is unique to SARS-CoV-2, providing specific neutralization.",
            "It is partially conserved, offering limited cross-reactivity."
        ],
        "What potential application is suggested for the structural insights gained from Cv2.3194 and Cv2.3132 antibodies?": [
            "Designing nanobodies targeting the SARS-CoV-2 spike protein.",
            "Developing vaccines using the spike protein structure.",
            "Creating antiviral drugs that inhibit spike protein synthesis.",
            "Engineering T-cell therapies targeting spike protein epitopes."
        ],
        "Which region does the Cv2.3132 antibody target in the SARS-CoV-2 spike protein?": [
            "Heptad repeat 2 (HR2) region",
            "Receptor-binding domain (RBD)",
            "N-terminal domain (NTD)",
            "S1 subunit"
        ]
    }
}